中国中药(00570)今日盘中大跌5.85%,引发市场广泛关注。
公司发盈警,预计2024年度净利润同比将大跌90%至100%,最坏情况几乎没有盈利,其中经调整净利润亦将大跌50%至60%。
造成当年净利大幅缩水的主因有三:首先,集中采购降价、市场竞争加剧以及药材成本不断攀升等多重因素,对公司主力产品中药配方颗粒业务的销量和利润率带来较大冲击。其次,公司当年计提了较高金额的信用减值、商誉减值及厂房减值等减值准备。最后,部分附属公司补缴税款的支出亦对净利润造成较大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.